Document Detail


Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival.
MedLine Citation:
PMID:  15164374     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A major side effect of ribavirin (RBV) treatment is anemia. While this anemia is thought to result from increased RBC turnover, RBC survival has not been determined in subjects receiving RBV due to the complexity of the techniques commonly used to quantitate RBC life span. We recently described a simple, rapid, non-invasive technique that utilizes measurements of alveolar carbon monoxide (CO) concentration to determine RBC survival. In the present report, this method was employed to assess RBC survival in patients receiving RBV for hepatitis C. Each of the 31 measurements of RBC survival in 12 subjects with RBV-associated anemia was below the lower limit of normal (77 days), and the average survival (46 +/- 14 days) in these subjects was only about 38% of that of healthy controls (122 +/- 23 days). Five hepatitis C patients not undergoing RBV treatment had normal RBC survivals (112 +/- 17 days). While the mean reticulocyte percentage was significantly elevated in subjects treated with RBV, 59% of these measurements fell within the limits of normal. We conclude that RBV-associated anemia consistently is associated with reduced RBC survival as determined from breath CO measurements and that this reduced survival frequently is not associated with an elevated reticulocyte count.
Authors:
Mark A Virtue; Julie K Furne; Samuel B Ho; Michael D Levitt
Related Documents :
8326584 - Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associa...
16015034 - Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
17908474 - Relationship between adrenal function and prognosis in patients with severe sepsis.
2026944 - Blood transfusion and survival after laryngectomy for laryngeal carcinoma.
12607634 - Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 p...
15514374 - Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfraction...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  American journal of hematology     Volume:  76     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-05-27     Completed Date:  2004-07-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  107-13     Citation Subset:  IM    
Affiliation:
Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antiviral Agents / therapeutic use*
Biological Markers
Breath Tests
Carbon Monoxide / analysis*
Cell Survival / drug effects
Erythrocytes / drug effects,  pathology*
Hemoglobins / analysis
Hepatitis C / blood,  drug therapy*
Humans
Male
Middle Aged
Regression Analysis
Ribavirin / therapeutic use*
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Biological Markers; 0/Hemoglobins; 36791-04-5/Ribavirin; 630-08-0/Carbon Monoxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The older sickle cell patient.
Next Document:  Mild hyperhomocysteinemia in adult patients with sickle cell disease: a common finding unrelated to ...